Tech and Growth 3.77K Followers
Summary
I re-rate CareCloud neutral: the $2.80 FY 2027 target implies 7% upside after the Q3 rally; wait for FY 2027 guidance.
CCLD's Q3 revenue grew 9% to $34 million, while gross margin reached 50.5% and operating income more than doubled to $7 million.
Further upside depends on shrinking revenue bottoming and AI and RCM cross-selling into Medsphere's customer base sustaining high-quality margin expansion.
Pro forma revenue declines and capitalized development costs cloud margin quality; $37 million of debt versus $5 million of cash remains an overhang.
andresr/E+ via Getty Images
I first covered CareCloud (CCLD) back in late January this year, initiating my coverage with a buy rating and a 1-year price target of $4.3 when the stock was trading around $2.9 per share.
As
This article was written by
Tech and Growth 3.77K Followers
We're a long-only asset manager allocating into tech and growth asset classes.…